|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0457343,
umls-concept:C0871261,
umls-concept:C1274040,
umls-concept:C1521991,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2603343,
umls-concept:C2911692
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-12-3
|
|
pubmed:abstractText |
This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 months during therapy. Sixty-six per cent (22/33) of the patients fulfiled our molecular response criterion of > or = 1 log decrease in bcr-abl transcript after 6 or > or = 2 log decrease after 9 and every following 3 months. Dose escalation was necessary for 33% (11/33) of the patients. Of these, 54% (6/11) achieved a reduction of bcr-abl mRNA by > or = 2 log (n = 3) or > or = 3 log (n = 3) with 800 mg Imatinib. Forty-five per cent (5/11) showed insufficient molecular response with 800 mg Imatinib and received Nilotinib. In conclusion, the assessment of molecular response permits an individual patient-tailored treatment of CML in first chronic phase, resulting in the majority of patients achieving a major molecular response after 2 years of therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0278-0232
|
|
pubmed:author |
pubmed-author:BruennertDanielaD,
pubmed-author:FenkRolandR,
pubmed-author:GattermannNorbertN,
pubmed-author:HaasRainerR,
pubmed-author:KochAnneA,
pubmed-author:KronenwettRalfR,
pubmed-author:MarkettJudithJ,
pubmed-author:NeumannFrankF,
pubmed-author:PootenMonikaM,
pubmed-author:Royer-PokoraBrigitteB,
pubmed-author:SchimkusNadineN,
pubmed-author:WulfertMichaelM
|
|
pubmed:copyrightInfo |
Copyright (c) 2008 John Wiley & Sons, Ltd.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
213-8
|
|
pubmed:meshHeading |
pubmed-meshheading:18449950-Adult,
pubmed-meshheading:18449950-Aged,
pubmed-meshheading:18449950-Antineoplastic Agents,
pubmed-meshheading:18449950-Blood Cell Count,
pubmed-meshheading:18449950-Drug Administration Schedule,
pubmed-meshheading:18449950-Female,
pubmed-meshheading:18449950-Fusion Proteins, bcr-abl,
pubmed-meshheading:18449950-Humans,
pubmed-meshheading:18449950-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:18449950-Male,
pubmed-meshheading:18449950-Middle Aged,
pubmed-meshheading:18449950-Mutation,
pubmed-meshheading:18449950-Piperazines,
pubmed-meshheading:18449950-Pyrimidines,
pubmed-meshheading:18449950-RNA, Messenger,
pubmed-meshheading:18449950-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study.
|
|
pubmed:affiliation |
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Moorenstr. Duesseldorf, Germany. frank.neumann@med.uni-duesseldorf.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
